Peptide T immunomodulation: inhibition of TNF alpha. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Peptide T immunomodulation: inhibition of TNF alpha.

Int Conf AIDS. 1993 Jun 6-11;9(1):173 (abstract no. PO-A13-0232). Unique Identifier : AIDSLINE MED/93333666
Phipps DJ; Doob PR; MacFadden DK; Department of Medicine, University of Toronto, Canada.

Abstract: OBJECTIVE: To determine the effect of Peptide T immunomodulation on TNF alpha in vitro. METHODS: Peptide T, diluted in RPMI, was used at 10(-9)M unless indicated. Cytotoxicity of 3H-thymidine labelled K562 cells, detected by release of radiolabel into culture supernatants, was used as a measure of macrophage and TNF alpha activity. TNF alpha activity was confirmed by inhibition with anti-TNF alpha. RESULTS: Peptide T added concurrently with target cells inhibited activated macrophage mediated cytotoxicity by 40%. This effect was also seen with VIP (10(-9)M). Peptide T mediated inhibition of TNF cytotoxicity was active from 10(-5) to 10(-13)M with maximal effect present from 10(-9)-10(-11)M. The presence of Peptide T inhibited the ability of TNF to activate macrophages (p = 0.0036). Peptide T treated K562 were less susceptible to cytotoxic effects of TNF alpha than mock treated cells. Peptide T reduced Con A induced TNF expression. CONCLUSIONS: Inhibition of TNF alpha appears to be a result of physiological effects on target cells rather than competitive inhibition. This work supports both VIPergic and immunomodulatory mechanisms of action of Peptide T and may explain the clinical benefit seen in patients with symptomatic HIV disease in open label trials.
Keywords: *Peptide T/PHARMACOLOGY *Tumor Necrosis Factor/ANTAGONISTS & INHIBKWDpeptidet/pharmacologyKWDtumornecrosisfactor/antagonists&inhib
931130
M93B5427

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .